145 related articles for article (PubMed ID: 23323066)
1. Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment.
Neves F; Menezes Neto OA; Polis LB; Bassi SC; Brunetta DM; Silva-Pinto AC; Angulo IL
Rev Bras Hematol Hemoter; 2012; 34(6):426-9. PubMed ID: 23323066
[TBL] [Abstract][Full Text] [Related]
2. Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros.
Santos FK; Maia CN
Rev Bras Hematol Hemoter; 2011; 33(2):105-9. PubMed ID: 23284256
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia.
Fibach E; Burke LP; Schechter AN; Noguchi CT; Rodgers GP
Blood; 1993 Mar; 81(6):1630-5. PubMed ID: 7680923
[TBL] [Abstract][Full Text] [Related]
5. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of hydroxyurea in children and adolescents with sickle/beta-thalassemia: two-year experience.
Papadopoulou E; Teli A; Theodoridou S; Gompakis N; Economou M
Hippokratia; 2015; 19(2):172-5. PubMed ID: 27418768
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pharmacological efficacy and safety of hydroxyurea in sickle cell disease: Study of a pediatric cohort from Chhattisgarh, India.
Lad H; Naskar S; Punyasri Pasupuleti SKDB; Nahrel R; Sihare P; Chandak GR; Patra PK
Pediatr Hematol Oncol; 2023 May; 40(4):395-406. PubMed ID: 36226857
[TBL] [Abstract][Full Text] [Related]
8. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
[TBL] [Abstract][Full Text] [Related]
9. "Minor" hemoglobinopathies: a risk factor for asthma.
Palma-Carlos AG; Palma-Carlos ML; Costa AC
Eur Ann Allergy Clin Immunol; 2005 May; 37(5):177-82. PubMed ID: 15984316
[TBL] [Abstract][Full Text] [Related]
10. Sickle Cell Disease in Central India: A Potentially Severe Syndrome.
Jain D; Warthe V; Dayama P; Sarate D; Colah R; Mehta P; Serjeant G
Indian J Pediatr; 2016 Oct; 83(10):1071-6. PubMed ID: 27053181
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric analysis of hydroxyurea effects on fetal hemoglobin production in cultures of beta-thalassemia erythroid precursors.
Amoyal I; Goldfarb A; Fibach E
Hemoglobin; 2003 May; 27(2):77-87. PubMed ID: 12779269
[TBL] [Abstract][Full Text] [Related]
12. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia.
Orringer EP; Blythe DS; Johnson AE; Phillips G; Dover GJ; Parker JC
Blood; 1991 Jul; 78(1):212-6. PubMed ID: 1712641
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
14. Red cell indices: differentiation between β-thalassemia trait and iron deficiency anemia and application to sickle-cell disease and sickle-cell thalassemia.
Sahli CA; Bibi A; Ouali F; Fredj SH; Dakhlaoui B; Othmani R; Laouini N; Jouini L; Ouenniche F; Siala H; Touhami I; Becher M; Fattoum S; Toumi Nel H; Messaoud T
Clin Chem Lab Med; 2013 Nov; 51(11):2115-24. PubMed ID: 23800659
[TBL] [Abstract][Full Text] [Related]
15. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
Ballas SK; Connes P;
Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
[TBL] [Abstract][Full Text] [Related]
16. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease.
Brown AK; Sleeper LA; Miller ST; Pegelow CH; Gill FM; Waclawiw MA
Arch Pediatr Adolesc Med; 1994 Aug; 148(8):796-804. PubMed ID: 7519102
[TBL] [Abstract][Full Text] [Related]
17. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
[TBL] [Abstract][Full Text] [Related]
18. Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia.
Powars DR; Schroeder WA; Weiss JN; Chan LS; Azen SP
J Clin Invest; 1980 Mar; 65(3):732-40. PubMed ID: 6153392
[TBL] [Abstract][Full Text] [Related]
19. Co-Inheritance of α-thalassemia gene mutation in patients with sickle cell Disease: Impact on clinical and hematological variables.
Ali Al-Barazanchi ZA; Abdulateef SS; Hassan MK
Niger J Clin Pract; 2021 Jun; 24(6):874-882. PubMed ID: 34121736
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
